$0.93
5.29%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US95075A1079
Symbol
HOWL

Werewolf Therapeutics Inc Stock price

$0.93
-0.07 7.03% 1M
-0.08 8.11% 6M
+0.29 46.50% YTD
-0.99 51.66% 1Y
-1.12 54.73% 3Y
-16.72 94.74% 5Y
-15.17 94.24% 10Y
-15.17 94.24% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
+0.05 5.29%
ISIN
US95075A1079
Symbol
HOWL
Industry

Is Werewolf Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$45.1m
Enterprise Value
$23.1m
Net debt
positive
Cash
$22.0m
Shares outstanding
48.6m
Valuation
P/E
negative
P/S | estimate
2.1 | -
EV/Sales | estimate
1.1 | -
EV/FCF | ex SBC
negative | negative
P/B
2.8
Financial Health
Equity Ratio
35.7%
Return on Equity
-245.2%
ROCE
-156.9%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$3.8m | 18.0%
SBC as % of FCF
-
SBC Growth 1Y
-50.9%
Share Count Growth 1Y
7.2%
Shareholder Yield
-7.2%
Financials
Revenue | estimate
$21.0m | $0.0
EBITDA
$-21.9m
EBIT
$-25.6m
Net Income
$-34.6m
Free Cash Flow | ex SBC
$-30.2m | $-33.9m
Growth
Revenue | estimate
- | -
EBITDA
69.2%
EBIT
65.0%
Net Income
52.7%
Free Cash Flow
50.5%
Margin
Gross
-
EBITDA
-104.4%
EBIT
-121.8%
Net
-164.8%
Free Cash Flow | ex SBC
-143.6% | -161.6%
More
EPS
$-0.7
FCF per Share
$-0.6
Short interest
4.2%
Employees
39
Rev per Employee
$0.0

Werewolf Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Werewolf Therapeutics Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Werewolf Therapeutics Inc forecast:

Buy
75%
Hold
25%

Financial data from Werewolf Therapeutics Inc

Jun '26
+/-
%
21 21
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
7% 7%
82%
- Research and Development Expense 29 29
46% 46%
140%
-22 -22
69% 69%
-104%
- Depreciation and Amortization 3.65 3.65
111% 111%
17%
EBIT (Operating Income) EBIT -26 -26
65% 65%
-122%
Net Profit -35 -35
53% 53%
-165%

In millions USD.

Don't miss a Thing! We will send you all news about Werewolf Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Werewolf Therapeutics Inc Stock News

Positive
Invezz
●
about one month ago
Werewolf Therapeutics (HOWL) stock exploded higher on Friday morning after management said the company has agreed to a definitive all-stock merger with Ambros Therapeutics. The combined company will pivot to focus on Ambros' Phase 3 drug candidate – neridronate – for Complex Regional Pain Syndrome Type 1 (CRPS-1), backed by an oversubscribed $150 million private placement from top-tier institut...
Neutral
GlobeNewsWire
●
about one month ago
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics' neridronate development program in Complex Regional Pain Syndrome Type...
Neutral
GlobeNewsWire
●
2 months ago
WATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported fin...
More Werewolf Therapeutics Inc News

Company Profile

Werewolf Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Dr. Hicklin
Employees 39
Founded 2017
Website werewolftx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today